BridGene Biosciences
San Jose, United States · Biotechnology, Therapeutics
BridGene Biosciences is a biotechnology company pioneering the discovery and development of innovative small-molecule drugs that target traditionally undruggable targets. Leveraging its proprietary IMTAC™ (Isobaric Mass-Tagged Affinity Characterization) chemoproteomic platform, BridGene screens covalent small molecules against the entire proteome in live cells to identify novel binding sites and d
Key facts
- Headquarters
- San Jose, United States
- Employees
- 33
- Industries
- Biotechnology, Therapeutics
- Status
- Private
- Website
- www.bridgenebio.com
- Company page
Recent activity at BridGene Biosciences
BridGene Biosciences funding history
| Date | Round | Amount |
|---|---|---|
| Oct 2025 | Series B | $28.0M |
| Jul 2022 | Series B | $38.5M |
Leadership
- Irene Yuan, Chief Operating Officer
- Ping Cao, Chief Executive Officer
Verified email and direct lines for BridGene Biosciences’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Employee benefit plans
BridGene Biosciences files 1 employee benefit plan with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
BridGene Biosciences in the news
- /C O R R E C T I O N -- BridGene Biosciences/ - PR Newswire (Jan 27, 2026)
- BridGene Biosciences Announces Strategic Collaboration with Takeda to Discover Small Molecule Drugs for Immunology and Neurology Targets - Lelezard (Feb 25, 2025)
- BridGene Biosciences Announces Strategic Collaboration with Galapagos to Discover Small Molecule Drugs for Oncology Targets - PR Newswire (Jan 03, 2024)
- BridGene Biosciences to Present Data from Two Preclinical Studies at 34th EORTC-NCI-AACR Symposium 2022 - Lelezard (Oct 07, 2022)
- BridGene Biosciences Announces Dosing of First Patient in Phase 1 Study Evaluating Novel TEAD Inhibitor BGC515 in Advanced Solid Tumors - PR Newswire (Jun 28, 2024)
Companies similar to BridGene Biosciences
- Inteliphage · Biotechnology, Therapeutics
- Barinthus Biotherapeutics plc · Biotechnology, Therapeutics
- n-Lorem Foundation · Biotechnology, Therapeutics
- Q32 Bio · Biotechnology, Therapeutics
- AIM ImmunoTech · Biotechnology, Therapeutics
About BridGene Biosciences: questions and answers
What does BridGene Biosciences do?
BridGene Biosciences is a biotechnology company pioneering the discovery and development of innovative small-molecule drugs that target traditionally undruggable targets. Leveraging its proprietary IMTAC™ (Isobaric Mass-Tagged Affinity Characterization) chemoproteomic platform, BridGene screens covalent small molecules against the entire proteome in live cells to identify novel binding sites and d
Where is BridGene Biosciences headquartered?
BridGene Biosciences is headquartered in San Jose, United States.
How many employees does BridGene Biosciences have?
BridGene Biosciences has about 33 employees.
Has BridGene Biosciences raised funding?
Yes. Fundz has recorded 2 funding events for BridGene Biosciences. The most recent, Series B of $28.0M, was in Oct 2025.
Who leads BridGene Biosciences?
Ping Cao is a Chief Executive Officer at BridGene Biosciences.
What is the latest news on BridGene Biosciences?
On Oct 16, 2025, BridGene Biosciences Raises $28 Million in Series B+ Financing Led by Bayland Capital to Advance BGC-515 and Expand Platform.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy